The factorial experiment, summarized in the study abstract, tested nitrogen rates of 0, 70, 150 and 250 kg N ha⁻¹ with biochar rates of 0 and 15 t ha⁻¹. Researchers measured nitrate leaching and assessed chlorophyll, relative water content and stomatal characteristics. Rhizome analyses covered phenolics, flavonoids, curcuminoids, oleoresin and antioxidant activity. Nitrogen rate, biochar rate and their interaction significantly influenced physiological traits and nitrate leaching, with the reported analysis giving p < 0.001.

Without biochar, measured nitrate loss rose from 360 mg N pot⁻¹ at the zero-nitrogen treatment to 2,906.67 mg N pot⁻¹ at 250 kg N ha⁻¹. With biochar, nitrate loss was 180–280 mg N pot⁻¹ across the tested nitrogen levels. The N150B15 treatment, combining 150 kg N ha⁻¹ with 15 t ha⁻¹ of biochar, recorded the highest chlorophyll content at 41.99 SPAD and relative water content at 92.61%. It also had the highest measured concentrations of phenolics at 39.65 mg gallic acid equivalents g⁻¹, flavonoids at 16.22 mg catechin equivalents g⁻¹ and curcuminoids at 61.67 mg curcuminoid equivalents g⁻¹. Oleoresin reached 61.89% in that treatment.

Antioxidant measurements were also highest under N150B15: 75.03% 2,2-diphenyl-1-picrylhydrazyl activity and 45.56 mg ascorbic acid equivalents g⁻¹ of ferric reducing antioxidant power. The abstract therefore reports improved measured physiology and rhizome phytochemical quality, together with reduced nitrate leaching, for moderate nitrogen combined with biochar in the tested sandy soil. These results are limited to a greenhouse pot experiment using one type and application rate of coffee husk biochar, one soil context and four nitrogen rates. The authors state that field-scale validation using diverse biochar types and rates is required before broader recommendations can be made; the supplied evidence does not establish field performance or wider applicability.

Subject of Research: Effects of coffee husk biochar and nitrogen rates on nitrate leaching and turmeric physiology and rhizome quality in a sandy-soil pot experiment

Article Title: Biochar and nitrogen effects on nitrate leaching, physiological performance, and rhizome quality of turmeric (Curcuma longa L.) in sandy soil

Article References: Eshetu, T., Dessalegn, E., Belew, D., Gobena, A., & Nigusie, A. (2026). Biochar and nitrogen effects on nitrate leaching, physiological performance, and rhizome quality of turmeric (Curcuma longa L.) in sandy soil. BMC Plant Biology. https://doi.org/10.1186/s12870-026-09940-6

Image Credits: AI Generated

DOI: 10.1186/s12870-026-09940-6

Keywords: turmeric, Curcuma longa, biochar, nitrogen fertilization, nitrate leaching, greenhouse pot experiment, sandy soil, rhizome quality, curcuminoids, chlorophyll, nitrogen, effects

The core of the problem lies in how piperine actually works. It does not primarily help nutrients cross the intestinal wall. Instead, it inhibits the body’s machinery for eliminating foreign compounds, including the liver enzyme CYP3A4, the related enzyme CYP2C9, and the efflux transporter P-glycoprotein. These systems act as shared metabolic gatekeepers for a large fraction of orally administered drugs. When piperine blocks them, co-administered substances accumulate in the bloodstream, whether or not they are the intended target. The author, Masaki Kaneko of KYB Medical Service and KYB Orthogenics in Tokyo, compares the mechanism to the well-known food–drug interactions caused by grapefruit juice and St. John’s wort, both of which also modulate CYP3A4 activity.

The clinical consequences are not hypothetical. In controlled human pharmacokinetic studies, ten days of piperine at 20 milligrams per day increased the area under the concentration–time curve of the anticonvulsant carbamazepine by about 48 percent. In patients with epilepsy, single doses of piperine significantly raised carbamazepine concentrations and prolonged its half-life, and piperine also increased exposure to the anticonvulsant phenytoin. For the anti-inflammatory drug diclofenac, co-administration increased drug exposure by roughly 66 percent and extended its half-life by 34 percent, consistent with CYP2C9 inhibition. Physiologically based pharmacokinetic modeling predicts that 20 milligrams of piperine daily would raise exposure to several CYP3A4 substrates by more than 25 percent, including increases of about 34 percent for nifedipine, 35 percent for cyclosporine, and 59 percent for simvastatin. The greatest concern involves narrow-therapeutic-index drugs such as phenytoin and carbamazepine, where even modest increases in blood levels can trigger toxicity, including nystagmus and ataxia. Similar caution applies to anticoagulants, digoxin, and immunosuppressants.

Of the 14 tabulated drug-interaction studies, 12 showed increased exposure to the co-administered medication, spanning rifampicin, propranolol, theophylline, nevirapine, midazolam, chlorzoxazone, and fexofenadine. Two exceptions are instructive. A two-day course of a combined curcuminoid–piperine preparation did not alter the pharmacokinetics of midazolam, flurbiprofen, or paracetamol, whereas three days of piperine alone increased midazolam exposure, a discrepancy that remains unexplained. And in breast cancer patients, curcumin plus piperine reduced exposure to endoxifen, the active metabolite of tamoxifen, by 12.4 percent, showing that the direction of an interaction cannot be assumed to be an increase.

The nutrient side of the evidence tells a strikingly different story. Kaneko compiled a structured summary of 22 human pharmacokinetic studies and classified them by funding and affiliation. Nearly all the studies reporting enhanced absorption of nutrients or phytochemicals were conducted or funded by the manufacturer of the piperine ingredient, enrolled small numbers of healthy volunteers, and used plasma concentration as a surrogate endpoint. The celebrated 2,000 percent curcumin figure was calculated against a baseline so low that curcumin given alone was barely detectable in the assay. For beta-carotene, a 14-day crossover study in men with low baseline values showed a greater serum response with piperine, and for coenzyme Q10 only the 21-day, 120-milligram arm showed an increase of about 30 percent, with shorter comparisons showing no significant effect. For vitamin B6, selenium, and vitamin C, the human evidence exists, as far as the author could determine, only in manufacturer summaries or conference abstracts rather than peer-reviewed reports.

Independent trials have largely failed to confirm the enhancement claims. In three crossover studies of curcumin formulations involving 12, 30, and 9 healthy adults, piperine-containing preparations did not differ significantly from native curcumin or standard extract. Solubility-based approaches performed far better: in one trial, micellar formulations achieved 57-fold higher curcumin exposure and gamma-cyclodextrin complexes 30-fold higher, without any piperine at all. When researchers measured unconjugated curcumin separately, it remained below 2 nanomolar in most participants even after 2,280 milligrams of curcumin with 20 milligrams of piperine, suggesting that earlier studies measuring total curcumin, conjugated and unconjugated together, may have overstated the effect. For resveratrol, 20 milligrams of piperine left plasma concentrations of the parent compound and its metabolites unchanged. A 2025 three-arm study drove the point home: curcuminoid exposure rose dramatically when the proportion of long-pepper extract increased from 1 to 10 percent, yet the high-piperine arm still did not outperform a piperine-free comparator extract given at less than half the curcuminoid dose.

Beyond drug interactions, a subtler hazard arises from inadvertent supplement–supplement combinations. Curcumin appears in small amounts in many blended products marketed for joint, skin, gut, or liver support, so consumers may ingest it without considering themselves turmeric users. If they separately take a piperine-containing supplement, they unknowingly recreate the turmeric–piperine combination that has been linked to liver injury. In a United States registry series of ten adjudicated cases of turmeric-associated liver injury, five patients were hospitalized and one died; three of the seven products analyzed also contained piperine, and the investigators raised the possibility that the combination contributes to rising case numbers, though causation is unproven and absolute incidence appears low. Rising supplement-associated liver injury was highlighted at the 2026 Congress of the European Association for the Study of the Liver, and for context, supplement-related liver failure leading to liver transplant waitlisting in the United States has increased roughly eightfold over the past quarter century.

Kaneko is careful to note that piperine is not inherently a problem ingredient. Its inclusion is scientifically defensible when several conditions are met together: the target ingredient should have a documented bioavailability limitation that is mechanistically addressable by inhibiting first-pass metabolism or efflux, rather than poor solubility; enhancement should have been demonstrated in humans for the specific chemical form and dose used, preferably by independent investigators and, for heavily conjugated compounds, using the unconjugated fraction as the endpoint; the intended population should be defined and should not include people likely to be taking narrow-therapeutic-index drugs metabolized by CYP3A4, CYP2C9, or transported by P-glycoprotein; and the piperine dose should be the lowest shown to be effective, with clear label disclosure. On the evidence reviewed, few current products satisfy the second condition.

The Perspective also challenges assumptions about premium distribution channels. Labels such as “practitioner-exclusive” or “physician-dispensed” are marketing designations, not regulatory categories, and in the author’s observation piperine has now entered Japan’s clinic-dispensed supplement market, where users are especially likely to be taking prescription medications. Japan’s Foods with Function Claims framework operates on a notification system without pharmaceutical-style premarket evaluation, and the good manufacturing practice requirements that became mandatory on 1 September 2026, following the 2024 health-damage cases linked to a functional food product, address manufacturing quality rather than formulation appropriateness. A product can be manufactured to a high standard, free of contamination and accurately labeled, while still being formulated in a scientifically questionable way.

The practical implications reach clinicians, consumers, and industry alike. Clinicians should routinely ask about supplement use, including practitioner-exclusive products, when reviewing medications. Consumers can check labels for “black pepper extract,” “Piper nigrum extract,” “piperine,” or branded piperine ingredients, and should avoid unintentionally combining a piperine-containing supplement with a separate curcumin product. Label warnings advising people on anticonvulsants, anticoagulants, or immunosuppressants to consult a clinician are endorsed as necessary but insufficient, since a warning on one product cannot address risk created by combining two individually innocuous products, and cannot predict whether an interaction will raise or lower drug exposure. Regulators, the author suggests, could require that any “enhanced absorption” claim be backed by human data for the specific form and dose in the product, and pharmacovigilance systems should capture supplement–drug and supplement–supplement co-exposures. The broader message is that supplement formulation should be a deliberate, expert-driven discipline grounded in nutritional science and pharmacology, rather than an accumulation of trending ingredients, and that the ability to explain the rationale for every component is what separates a thoughtfully formulated product from one that is merely well manufactured.

Subject of Research: Piperine as a bioavailability enhancer in dietary supplements and its drug interaction risks

Article Title: Enhancement without a rationale? Black pepper extract (piperine) in dietary supplements and the future of formulation: a perspective from Japan

Article References: Kaneko, M. (2026). Enhancement without a rationale? Black pepper extract (piperine) in dietary supplements and the future of formulation: a perspective from Japan. Frontiers in Nutrition, 13, Article 1981406. https://doi.org/10.3389/fnut.2026.1981406

Image Credits: AI Generated

DOI: 10.3389/fnut.2026.1981406

Keywords: piperine, black pepper extract, dietary supplements, bioavailability, CYP3A4, P-glycoprotein, drug interactions, curcumin, turmeric, liver injury, formulation, Japan

Researchers from the Indian Council of Agricultural Research-Indian Institute of Spices Research in Kozhikode, along with collaborators from agricultural universities across India, evaluated 21 turmeric genotypes representing diverse agro-ecological regions of the country under greenhouse conditions over two consecutive growing seasons from 2021 to 2023. The trial was conducted at a commercial greenhouse facility in Telangana, where a multi-span structure covered with UV-stabilized diffuse polyethylene film and insect-proof netting provided a regulated microclimate. Natural ventilation through lateral roll-up openings and retractable shade screens during peak solar hours maintained conditions that minimized the environmental variability that typically plagues open-field cultivation.

The genotypes were grown in 24-liter plastic pots filled with sterilized coir husk chips, arranged in a completely randomized design with two replicates. Each genotype was planted in 40 pots with single 30-day-old sprouted rhizomes, and standard agronomic practices along with fertigation were followed throughout the crop cycle. The researchers meticulously recorded fresh rhizome yield, dry recovery percentage, oleoresin content, essential oil content, and curcuminoid concentration—the trio of quality parameters that determine turmeric’s commercial and medicinal value.

The results revealed striking genetic diversity across all measured traits. Fresh rhizome yield ranged from 378 to 1,014 grams per clump across the pooled analysis, while dry recovery varied between 15 and 28 percent. Oleoresin content spanned from 3 to 12 percent, essential oil from 2 to 9.5 percent, and curcuminoid content from 0.7 to 4.0 percent. Two genotypes—IISR Pragati and NDH 8—emerged as consistently high-yielding and stable performers. IISR Pragati recorded the highest pooled fresh rhizome yield at 959.08 grams per clump, followed closely by NDH 8 at 938.83 grams per clump, demonstrating that these varieties could reliably deliver top productivity even under the reduced environmental fluctuations of greenhouse cultivation.

On the quality front, Waigon Turmeric stood out with consistently superior oleoresin and essential oil contents, achieving pooled means of 12.07 percent and 8.50 percent respectively. Meanwhile, IISR Pragati demonstrated the highest and most stable curcuminoid content at 3.24 percent across both seasons, a finding of particular significance for pharmaceutical applications where curcumin concentration is the primary value driver. Chhattisgarh Haldi 2 showed exceptional dry recovery at 25.32 percent, making it attractive for processing industries where the ratio of dried to fresh rhizome directly affects economic returns.

Perhaps the most revealing finding came from the statistical decomposition of variation. Using pooled analysis of variance across the two seasons, the researchers found that genotype effects accounted for the majority of total variation in all five traits—58.28 percent for fresh rhizome yield, 75.31 percent for dry recovery, 60.41 percent for oleoresin, 77.28 percent for essential oil, and a remarkable 80.97 percent for curcuminoid content. Genotype-by-season interaction contributed a further 9 to 24 percent depending on the trait, while the season effect itself was comparatively minor. This stands in sharp contrast to open-field studies, where environmental factors and their interactions with genotype typically dominate the variation in yield and quality traits.

The researchers employed GGE biplot analysis to visualize these relationships graphically, confirming that genotype and genotype-by-environment interaction contributed more to trait variation than the environment itself under greenhouse conditions. This finding carries profound implications for breeding strategy. In traditional field cultivation, breeders must select for phenotypic stability—the ability of a genotype to perform consistently across unpredictable and changing environments. Under controlled conditions, however, the breeding paradigm shifts entirely. With environmental flux, pests, and pathogens less formidable barriers, breeders can focus on maximizing genetic potential for specific traits such as rapid growth, performance under modified light spectra, and optimized plant architecture.

Correlation analysis further illuminated the complex physiological trade-offs inherent in turmeric improvement. Fresh rhizome yield exhibited a significant positive association with curcuminoid content, but was negatively correlated with dry recovery, oleoresin content, and essential oil content. This inverse relationship between yield and certain quality parameters suggests a dilution effect, where rapidly growing rhizomes with higher moisture content accumulate lower concentrations of secondary metabolites per unit mass. Such trade-offs have long frustrated breeders attempting to improve both productivity and phytochemical quality simultaneously, and they underscore the necessity of multi-trait selection approaches that can identify genotypes achieving an optimal balance rather than excelling in a single dimension at the expense of others.

To address this challenge, the researchers applied two modern multi-trait selection indices—the Multi-Trait Genotype-Ideotype Distance Index (MGIDI) and the Factor Analysis and Ideotype-Design based on Best Linear Unbiased Prediction (FAI-BLUP). Factor analysis revealed two principal dimensions underlying the trait variation, together explaining 82.82 percent of total phenotypic variation. The first factor was primarily associated with fresh rhizome yield, curcuminoid content, and dry recovery, while the second factor captured oleoresin and essential oil content. At a selection intensity of 20 percent, the MGIDI identified Roma, Waigon Turmeric, IISR Prathiba, and CO 3 as the most promising genotypes. The FAI-BLUP index, using an ideotype targeting simultaneous increases in yield and quality traits, identified Roma, IISR Prathiba, CO 3, and IISR Pragati. The two models showed 75 percent concordance, with Roma, IISR Prathiba, and CO 3 consistently selected by both approaches across seasons.

The predicted genetic gains from multi-trait selection were substantial for quality parameters. Curcuminoid content showed a predicted gain of 33.56 percent, oleoresin content 11.54 percent, and essential oil content 9.37 percent. These gains came at a modest cost—fresh rhizome yield declined by 4.72 percent and dry recovery by 3.30 percent among the selected genotypes. However, in the economics of protected cultivation, where quality consistency commands premium pricing and pharmaceutical buyers demand reliable phytochemical profiles, this trade-off represents a favorable exchange. The researchers note that the modest sacrifice in raw yield can be compensated by the marked recovery in curcuminoid content per unit area, along with greater predictability in quality traits that reduces commercial risk.

This study represents the first systematic evaluation of turmeric genotypes for yield and quality under controlled greenhouse conditions, and its findings carry implications that extend far beyond the spice itself. As controlled-environment agriculture expands globally to meet the demands of growing urban populations and increasingly quality-conscious consumers, the principles demonstrated here—that genotype selection becomes the dominant determinant of both yield and phytochemical quality when environmental noise is minimized—apply broadly to other high-value specialty crops. The research also highlights the importance of tailoring breeding objectives to production systems: varieties optimized for open-field stability may not be the same ones that excel under the regulated conditions of a modern greenhouse. For India, which produces 80 percent of the world’s turmeric and leads global exports, these findings offer a roadmap for enhancing the consistency and pharmaceutical value of one of its most iconic spice crops, potentially transforming how turmeric is grown, graded, and marketed in the decades ahead.

Subject of Research: Genetic stability of yield and phytochemical quality traits in turmeric genotypes under controlled greenhouse cultivation

Article Title: Yield and quality traits stability of turmeric (Curcuma longa L.) genotypes under greenhouse conditions

Article References: Silaru, R., Sounderarajan, A., Kotha Madduri, Y., & Duraisamy, P. (2026). Yield and quality traits stability of turmeric (Curcuma longa L.) genotypes under greenhouse conditions. Frontiers in Horticulture, 5, Article 1899925. https://doi.org/10.3389/fhort.2026.1899925

Image Credits: AI Generated

DOI: 10.3389/fhort.2026.1899925

Keywords: turmeric, Curcuma longa, greenhouse cultivation, curcuminoids, genotype-environment interaction, yield stability, oleoresin, essential oil, MGIDI, FAI-BLUP, controlled environment agriculture, plant breeding

The research team, led by Jiayi Song and colleagues at Xiyuan Hospital of the China Academy of Chinese Medical Sciences, together with collaborators at Beijing University of Chinese Medicine, pooled data from 20 randomized controlled trials involving 1,414 patients. The team searched nine databases from their inception through July 2025, including Web of Science and several Chinese-language sources such as the China National Knowledge Infrastructure, the China Science and Technology Journal Database, and the China Biomedical Medicine database. The trials covered both radiation dermatitis, the skin damage that develops over irradiated areas, and radiation oral mucositis, the painful ulceration of the mouth and throat that afflicts many patients treated for head and neck cancers.

The headline finding is striking in its statistical consistency. Patients who received curcumin were significantly less likely to develop severe radiation injury, with a risk ratio of 0.55, meaning the odds of severe injury were cut nearly in half. The 95 percent confidence interval ran from 0.44 to 0.68, and, notably, the heterogeneity statistic I-squared was 0.0 percent, indicating that the included trials produced remarkably uniform results on this outcome. In clinical research, where heterogeneity across trials often muddies pooled estimates, a zero percent heterogeneity figure for a primary outcome is unusual and lends considerable weight to the conclusion.

Beyond preventing severe injury outright, curcumin appeared to blunt the overall severity of radiation damage when used prophylactically, before and during the course of radiotherapy. The standardized mean difference in severity scores was -0.81, with a confidence interval of -1.08 to -0.53, a moderate-to-large effect by conventional benchmarks, though the heterogeneity here was high at 84.1 percent, signaling substantial variation in how the trials measured and reported severity. When curcumin was used therapeutically, that is, to treat injuries that had already developed, the pooled analysis of the limited available trials showed a reduction in severity scores with a standardized mean difference of -1.06, with zero heterogeneity, although the wide confidence interval of -2.03 to -0.08 and the small number of therapeutic trials temper enthusiasm.

Pain relief emerged as another consistent benefit. Among patients using curcumin preventively, pain scores improved with a standardized mean difference of -1.06, and among those using it to treat established injury, the mean difference in pain scores was -2.22 on the scales used, with zero heterogeneity and a confidence interval running from -1.90 to -2.53. For patients whose mucositis makes swallowing agonizing or whose irradiated skin cracks and weeps, an analgesic effect of this magnitude, delivered by a dietary compound rather than an opioid, would represent a meaningful improvement in quality of life during an already grueling treatment course.

The methodological apparatus behind the analysis deserves attention, because it reflects the current gold standard in evidence synthesis. The authors assessed the risk of bias in each trial using the Cochrane Risk of Bias 2.0 tool and graded the certainty of the evidence with the GRADE framework. Rather than relying on a naive pooling method, they performed a random-effects meta-analysis with the Hartung-Knapp adjustment, a technique that produces more conservative and better-calibrated confidence intervals when the number of studies is small. All computations were carried out in R version 4.5.1, and the protocol was prospectively registered as CRD42024601503.

The team also interrogated the data for the distortions that plague meta-analyses of complementary therapies. Publication bias, the tendency for positive studies to be published while negative ones languish in file drawers, was assessed with funnel plots, Egger’s regression test applied when at least ten studies were available, and the trim-and-fill method, which estimates how many hypothetical missing studies would be needed to restore symmetry. Galbraith plots were used to visualize heterogeneity, and leave-one-out sensitivity analyses were performed to identify whether any single influential trial was driving the pooled results. This layered approach to robustness testing is precisely the kind of scrutiny that separates credible syntheses from the promotional meta-analyses that have historically inflated claims about natural products.

Safety, a perennial question for any compound proposed for use alongside cancer treatment, appears reassuring but under-documented. The incidence of adverse events showed no significant difference between curcumin and control groups, with a risk ratio of 0.84 and a confidence interval of 0.01 to 96.58. The authors themselves flag the problem: that extraordinarily wide interval reflects limited adverse event reporting across the included trials rather than genuine uncertainty about harm. The finding should therefore be read as an absence of detected signals rather than proof of safety, and the authors explicitly caution that the safety evidence requires careful interpretation. Curcumin is also known to interact with certain drug-metabolizing pathways, which makes systematic adverse event collection in future trials essential.

The biological plausibility of the findings rests on curcumin’s well-characterized anti-inflammatory and antioxidant pharmacology. Ionizing radiation kills tumor cells in part by generating reactive oxygen species, but those same radicals damage healthy tissue in the radiation field, triggering inflammation, lipid peroxidation, and impaired wound healing. Curcumin scavenges free radicals and modulates inflammatory signaling pathways, which is the mechanistic rationale for using it as a radioprotector. The drug-medicine continuum framing adopted by the authors is apt: turmeric has been consumed as a spice and used in traditional medicine for centuries, and its principal constituent now faces the same randomized-trial scrutiny as any pharmaceutical candidate.

The caveats remain substantial. Heterogeneity was high for several outcomes, potential publication bias was detected, and the GRADE assessment of evidence quality was constrained by the limitations of the underlying trials. The authors conclude that curcumin may prevent the occurrence of severe radiation injury and may reduce injury severity and pain in both prophylactic and therapeutic use, but they insist the conclusions be interpreted with caution. Still, the convergence of a halved risk of severe injury, consistent pain relief, and no detected excess of adverse events across 20 trials and more than 1,400 patients makes a compelling case that this kitchen-spice derivative has earned a place in large, rigorously designed confirmatory trials. If those trials replicate the effect, radiotherapy’s most common side effects could one day be softened by one of the oldest remedies in the pantry.

Subject of Research: Clinical efficacy and safety of curcumin for preventing and treating radiation injury in cancer patients

Article Title: Clinical efficacy and safety of curcumin for the prevention and treatment of radiation injury: a systematic review and meta-analysis of randomized controlled trials

Article References: Song, J., Fu, L., Dong, J., Hu, Y., Liu, L., Shi, J., Gu, S., Zhang, Z., Bu, Z., Liu, Z., & Xu, Y. (2026). Clinical efficacy and safety of curcumin for the prevention and treatment of radiation injury: a systematic review and meta-analysis of randomized controlled trials. BMC Complementary Medicine and Therapies. https://doi.org/10.1186/s12906-026-05528-7

Image Credits: AI Generated

DOI: 10.1186/s12906-026-05528-7

Keywords: curcumin, radiation injury, radiotherapy, meta-analysis, randomized controlled trials, radiation dermatitis, oral mucositis, radioprotection, turmeric, cancer supportive care, GRADE evidence, publication bias